SecBot SecBot

LTRN drug pipeline

Lantern Pharma Inc. · 2 rated drugs
$0.3650
−6.2% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±22.3%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnknown — still in Phase 1 dose-escalation. If Phase 1 completes successfully, Phase 2/3 would follow, meaning at least 3-5 years to potential approval, if ever.

LP-284 Updated Sep 13

What to watch

Watch for the next Phase 1 data update from LP-284's ongoing trial (NCT06132503), likely at a hematology/oncology medical conference in H1 2027. The stock is highly speculative at ~$1.71 with a ~923% implied analyst upside, but Phase 1 assets carry high failure risk. Monitor cash runway, Lantern's May 2026 offering raised capital but also diluted existing holders. Any meaningful partnership or accelerated development pathway would be a major positive catalyst.

Bull case
  • Early efficacy signal is compelling: a complete metabolic response in a DLBCL patient who had exhausted CAR-T and bispecific antibody therapies, a very difficult-to-treat population (source: Lantern Pharma press release, Oct 2025 LL&M Congress)
  • Three FDA Orphan Drug Designations (mantle cell lymphoma, high-grade B-cell lymphoma, soft tissue sarcomas) provide market exclusivity potential and development incentives (source: FDA catalysts data, SEC filings)
  • Analyst consensus is strongly bullish: 7 of 8 analysts rate Buy/Strong Buy with a mean price target of $17.50, implying ~923% upside from $1.71
Bear case
  • Phase 1 only, the vast majority of Phase 1 oncology drugs never achieve FDA approval; early single-patient complete responses often fail to replicate in larger cohorts
  • Micro-cap risk: LTRN trades near $1.71 with a ~$22M market cap; the May 2026 securities offering that raised capital also diluted existing shareholders (insider warrants at $2.27 strike)
  • Mixed institutional signals: BlackRock trimmed -50.6% and Dimensional Fund Advisors trimmed -56.1% of their LTRN positions in Q2 2026
● neutral
Impact
PhasePhase 1 (IND cleared, trial not yet initiated)
Time to marketUnknown — Phase 1 trial has not started; typical development timeline for a rare pediatric cancer drug from Phase 1 to approval is 5-10+ years, if successful.

STAR-001 Updated Sep 13

What to watch

STAR-001 has no scheduled near-term binary catalyst, the IND was cleared in March 2026 but Phase 1 trial enrollment and initial data are likely 12+ months away. The stock is more driven by LP-300 HARMONIC trial data, LP-184 regulatory progress, and the company's cash runway (only through mid-Q1 2027). Monitor for Phase 1 trial initiation announcements and any partnership/licensing deals that could fund development.

Bull case
  • FDA IND clearance on March 30, 2026, was a positive regulatory milestone that de-risked the program and allowed the Phase 1 trial to proceed, stock reacted with +22% one-day and +45% five-day gains.
  • ATRT is a rare, aggressive pediatric cancer with no approved targeted therapies, representing a high unmet medical need and potential for expedited regulatory pathways (rare pediatric disease designation, priority review voucher).
  • Lantern Pharma's RADR AI platform may enable efficient patient selection and biomarker-driven development, potentially improving trial success probabilities.
Bear case
  • STAR-001 is at the earliest clinical stage (Phase 1 not yet initiated), most oncology drugs fail in Phase 1/2, and pediatric CNS cancer trials face additional enrollment challenges.
  • Lantern Pharma had only $7.4M in cash as of June 30, 2026, with runway only through mid-Q1 2027, the company will likely need to raise capital, causing dilution, before STAR-001 generates any data.
  • The company has no approved products or revenue; it is a pre-commercial biotech entirely dependent on pipeline success and external financing.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Mar 30, 2026STAR-001Clinical hold+22.3%+57.1%
Mar 30, 2026LP-284Orphan drug designation+22.3%+57.1%